Search results for "CYP3A"

showing 10 items of 59 documents

Pharmacogenetic Study of ABCB1 and CYP3A5 Genes During the First Year Following Heart Transplantation Regarding Tacrolimus or Cyclosporine Levels

2011

Pharmacogenetics explains part of the interindividual variability in drug responses. Many published works about the effects of single nucleotide polymorphisms (SNPs) on immunosuppressive drug blood levels present contradictory results. We evaluated the SNPs in ABCB1 (glycoprotein P) and CYP3A5 (metabolic enzyme) genes, seeking correlate them with tacrolimus or cyclosporine levels during the first year after heart transplantation. One blood sample was obtained from each of 41 patients: 26 treated with cyclosporine and 15 with tacrolimus. We characterize the SNPs rs1045642, 1128503, 2032582, 2235013, 2235033, 2229109, 3213619, 9282564 in ABCB1 and rs10264272, 776746 in CYP3A5 genes using the …

Linkage disequilibriummedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentSingle-nucleotide polymorphismBiologyPharmacologyPolymorphism Single NucleotideGastroenterologyLinkage DisequilibriumTacrolimusGene FrequencyInternal medicineGenotypemedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1CYP3A5Heart transplantationTransplantationTacrolimusPhenotypeImmunosuppressive drugPharmacogeneticsSpainCyclosporineHeart TransplantationSurgeryDrug MonitoringImmunosuppressive AgentsPharmacogeneticsTransplantation Proceedings
researchProduct

Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved.

2002

The hepatic drug-metabolizing cytochrome P-450 (CYP) enzymes are down-regulated during inflammation. In vitro studies with hepatocytes have shown that the cytokines released during inflammatory responses are largely responsible for this CYP repression. However, the signaling pathways and the cytokine-activated factors involved remain to be properly identified. Our research has focused on the negative regulation of CYP3A4 (the major drug-metabolizing human CYP) by interleukin 6 (IL-6) (the principal regulator of the hepatic acute-phase response). CYP3A4 down-regulation by IL-6 requires activation of the glycoprotein receptor gp130; however, it does not proceed through the JAK/STAT pathway, a…

MAPK/ERK pathwaySTAT3 Transcription FactorMAP Kinase Signaling Systemp38 mitogen-activated protein kinasesDown-RegulationBiologyBiochemistryTransactivationCytochrome P-450 Enzyme SystemAntigens CDGeneticsCCAAT-Enhancer-Binding Protein-alphaCytokine Receptor gp130Tumor Cells CulturedCytochrome P-450 CYP3AHumansRNA MessengerSTAT3Molecular BiologyTranscription factorCells CulturedMembrane GlycoproteinsDose-Response Relationship DrugInterleukin-6Reverse Transcriptase Polymerase Chain ReactionCCAAT-Enhancer-Binding Protein-betaJAK-STAT signaling pathwayProtein-Tyrosine KinasesGlycoprotein 130Molecular biologyDNA-Binding ProteinsGene Expression Regulationbiology.proteinHepatocytesTrans-ActivatorsSignal transductionBiotechnologyAcute-Phase ProteinsSignal TransductionTranscription FactorsFASEB journal : official publication of the Federation of American Societies for Experimental Biology
researchProduct

The effect of CYP3A5 and ABCB1 single nucleotide polymorphisms on tacrolimus dose requirements in Caucasian liver transplant patients

2008

Background: Tacrolimus is a substrate of cytochrome P-450 (CYP) 3A enzyme and of the drug transporter ABCBl. We have investigated the effects of possible relevant CYP3A5 and ABCBl single nucleotide polymorphisms (SNPs) present in both donors and recipients on tacrolimus blood levels achieved in a population of 32 Caucasian liver transplant patients. Material/Methods: At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were determined. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for gen-otyping CYP3A5*3 [6986A>G] as well as ABCBl at exons 21 [2677G>T] and 26 [3435C>T]. Results:87.5…

MaleCYP3A5ATP Binding Cassette Transporter Subfamily BGenotypeHomozygoteABCB1Polymorphism Single NucleotideTacrolimusWhite PeopleLiver Transplantationliver transplantPharmacogeneticssingle nucleotide polymorphismTacrolimuSettore BIO/14 - FarmacologiaCytochrome P-450 CYP3AHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1Tacrolimus; single nucleotide polymorphisms; CYP3A5; ABCB1; liver transplantImmunosuppressive Agents
researchProduct

Pregnane X receptor and yin yang 1 contribute to the differential tissue expression and induction of CYP3A5 and CYP3A4.

2012

The hepato-intestinal induction of the detoxifying enzymes CYP3A4 and CYP3A5 by the xenosensing pregnane X receptor (PXR) constitutes a key adaptive response to oral drugs and dietary xenobiotics. In contrast to CYP3A4, CYP3A5 is additionally expressed in several, mostly steroidogenic organs, which creates potential for induction-driven disturbances of the steroid homeostasis. Using cell lines and mice transgenic for a CYP3A5 promoter we demonstrate that the CYP3A5 expression in these organs is non-inducible and independent from PXR. Instead, it is enabled by the loss of a suppressing yin yang 1 (YY1)-binding site from the CYP3A5 promoter which occurred in haplorrhine primates. This YY1 sit…

MaleReceptors SteroidDrugs and DevicesMolecular Sequence Datalcsh:MedicineSequence HomologyMice TransgenicBiologyModels BiologicalMolecular GeneticsMiceDogsGene expressionMolecular Cell BiologyGeneticsAnimalsCytochrome P-450 CYP3AHumansTissue DistributionEvolutionary SystematicsPharmacokineticsEnzyme inducerBinding sitelcsh:ScienceBiologyCYP3A5 GeneCells CulturedPhylogenyYY1 Transcription FactorPregnane X receptorEvolutionary BiologyMultidisciplinaryCYP3A4Base SequenceYY1lcsh:RPregnane X ReceptorComputational BiologyPromoterMolecular biologyOrganismal EvolutionMice Inbred C57BLNephrologyEnzyme Inductionbiology.proteinMedicinelcsh:QFemaleResearch ArticlePloS one
researchProduct

Modelling intestinal absorption of salbutamol sulphate in rats

2005

The objective was to develop a semiphysiological population pharmacokinetic model that describes the complex salbutamol sulphate absorption in rat small intestine. In situ techniques were used to characterize the salbutamol sulphate absorption at different concentrations (range: 0.15-18 mM). Salbutamol sulphate at concentration of 0.29 mM was administered in presence of verapamil (10 and 20 mM), grapefruit juice and sodium azide (NaN3) (0.3, 3 and 6 mM). Different pharmacokinetic models were fitted to the dataset using NONMEM. Parametric and non-parametric bootstrap analyses were employed as internal model evaluation techniques. The validated model suggested instantaneous equilibrium betwee…

Malefood.ingredientEnterocytePopulationBiological AvailabilityBiological Transport ActivePharmaceutical ScienceLumen (anatomy)PharmacologyModels BiologicalGrapefruit juiceIntestinal absorptionBeveragesfoodPharmacokineticsIntestine SmallmedicineAnimalsCytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsAlbuterolATP Binding Cassette Transporter Subfamily B Member 1Rats WistarSodium Azideeducationeducation.field_of_studyChromatographyDose-Response Relationship DrugChemistryAdrenergic beta-AgonistsRatsBioavailabilitymedicine.anatomical_structureIntestinal AbsorptionVerapamilSalbutamolCitrus paradisimedicine.drugInternational Journal of Pharmaceutics
researchProduct

Genetic Polymorphisms and Individualized Tacrolimus Dosing

2010

Background. Genetic polymorphisms of metabolism enzymes or intestinal drug transporters may affect pharmacokinetic responses to immunosuppressive drugs in renal transplant recipients. We sought to identify the frequency of genetic polymorphisms and their importance for individualization of tacrolimus doses. Patients and Methods. We performed an observational study in 35 renal transplant recipients treated with tacrolimus, mycophenolate mofetil, and corticosteroids. Tacrolimus concentrations were determined by immunoanalysis (IMx method; Abbott Diagnostics, Abbott Park, Ill), on 11 blood samples per patient during the first 6 weeks after renal transplantation. For each patient, we calculated…

Malemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BBiologyPolymorphism Single NucleotideGastroenterologyTacrolimusIntestinal absorptionCohort StudiesPharmacokineticsInternal medicinemedicineCytochrome P-450 CYP3AHumansATP Binding Cassette Transporter Subfamily B Member 1Antibacterial agentTransplantationProtein synthesis inhibitorMiddle AgedTacrolimusCalcineurinTransplantationsurgical procedures operativePharmacogeneticsImmunologyFemaleSurgeryImmunosuppressive AgentsPharmacogeneticsTransplantation Proceedings
researchProduct

Permissive and suppressive effects of dexamethasone on enzyme induction in hepatocyte co-cultures.

2002

1. Steroids are known to act as permissive factors in hepatocytes. This study shows that dexamethasone (DEX) is a permissive factor for induction of CYP2B1/2, CYP3A1, CYP2A1 and probably also CYP2C11 in cultures with primary rat hepatocytes. 2. The induction factor of phenobarbital (PB)-induced formation of 16beta-hydroxytestosterone (OHT), a testosterone biotransformation product predominantly formed by CYP2B1, is increased 18-fold by the addition of 32 nM DEX to the culture medium. Interestingly, higher concentrations of DEX up to 1000 nM led to a concentration-dependent maximally 5-fold decrease (p = 0.002) of phenobarbital-induced 16beta-OHT formation compared with the effect observed w…

Malemedicine.medical_specialtyTime FactorsHealth Toxicology and MutagenesisAnti-Inflammatory AgentsBiologyToxicologyBiochemistryDexamethasoneRats Sprague-DawleyEnzyme activatorInternal medicinepolycyclic compoundsmedicineCytochrome P-450 CYP1A1AnimalsCytochrome P-450 CYP3AProtein IsoformsPermissiveEnzyme inducerCytochrome P450 Family 2DexamethasoneCells CulturedPharmacologyCryopreservationDose-Response Relationship DrugBiological activityGeneral MedicineIn vitroCoculture TechniquesRatsEnzyme ActivationEndocrinologymedicine.anatomical_structureLiverSteroid 16-alpha-HydroxylaseHepatocytePhenobarbitalCytochrome P-450 CYP2B1Steroid Hydroxylasesbiology.proteinHepatocytesHydroxytestosteronesAryl Hydrocarbon HydroxylasesExcitatory Amino Acid Antagonistshormones hormone substitutes and hormone antagonistsGlucocorticoidmedicine.drugXenobiotica; the fate of foreign compounds in biological systems
researchProduct

Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity

2014

Item does not contain fulltext OBJECTIVES: The reduction in mother-to-child transmission of HIV-1 by single-dose nevirapine given at birth onset is achieved at the expense of de novo HIV-1 resistance mutations. In the VITA1 study, single-dose carbamazepine accelerated nevirapine elimination, but the accompanying trend towards fewer de novo HIV-1 mutations was statistically non-significant. METHODS: We investigated if the effect of carbamazepine was confounded by the individual variability in nevirapine metabolism and transport. RESULTS: Nine of 34 (26%) single-dose nevirapine-treated women had one or more nevirapine-associated resistance mutations, compared with 3 of 34 (9%) in the single-d…

Microbiology (medical)NevirapineCYP3AAnti-HIV AgentsHuman immunodeficiency virus (HIV)Mutation MissenseEndogenyHIV InfectionsPharmacologyBiologymedicine.disease_causeChemopreventionPregnancyDrug Resistance ViralmedicineClinical endpointCytochrome P-450 CYP3AHumansPharmacology (medical)NevirapinePharmacologyMutationCYP3A4Cytochrome P-450 CYP3A InducersCarbamazepinelnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesCarbamazepineTreatment OutcomeHIV-1Femalemedicine.drug
researchProduct

Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies …

1996

Important species differences have been reported concerning the induction properties of rifampicin towards enzymes of the P-450 superfamily. Mice, rabbits and humans are far more responsive than rats and guinea pigs. In the present study a strong induction of cytochrome P-450 3A-dependent enzyme activities was observed in female rat liver microsomes after high dose treatment (> or = 250 mg/kg/day for 9 days) with rifampicin, resulting in an up to 30-fold enhanced hydroxylation rate of testosterone in the 2 beta-, 6 beta- and 15 beta-position in vitro. Other cytochrome P-450 isozyme-selective reactions were not, or only marginally, affected. A steep increase in cytochrome P-450 3A activity o…

Microbiology (medical)RifabutinCYP3AGlucuronidation10050 Institute of Pharmacology and Toxicology610 Medicine & healthPharmacologyBiology2726 Microbiology (medical)Cytochrome P-450 Enzyme Systempolycyclic compoundsmedicineAnimals2736 Pharmacology (medical)TestosteronePharmacology (medical)GlucuronosyltransferaseRats WistarEnzyme inducerAntibiotics AntitubercularAntibacterial agentPharmacologyDose-Response Relationship DrugCytochrome P4502725 Infectious Diseasesbacterial infections and mycosesRatsInfectious Diseases3004 PharmacologyLiverRifabutinMicrosomebiology.protein570 Life sciences; biologyFemaleRifampinRifampicinmedicine.drug
researchProduct

Ligand Diversity of Human and Chimpanzee CYP3A4: Activation of Human CYP3A4 by Lithocholic Acid Results from Positive SelectionS⃞

2009

For currently unknown reasons, the evolution of CYP3A4 underwent acceleration in the human lineage after the split from chimpanzee. We investigated the significance of this event by comparing Escherichia coli-expressed CYP3A4 from humans, chimpanzee, and their most recent common ancestor. The expression level of chimpanzee CYP3A4 was ∼50% of the human CYP3A4, whereas ancestral CYP3A4 did not express in E. coli. Steady-state kinetic analysis with 7-benzyloxyquinoline, 7-benzyloxy-4-(trifluoromethyl)coumarin (7-BFC), and testosterone showed no significant differences between human and chimpanzee CYP3A4. Upon addition of α-naphthoflavone (25 μM), human CYP3A4 showed a slightly decreased substr…

Most recent common ancestorModels MolecularLithocholic acidLineage (genetic)Pan troglodytesmedicine.drug_classPharmaceutical ScienceLigandsIsozymechemistry.chemical_compoundSpecies SpecificityCoumarinsmedicineAnimalsCytochrome P-450 CYP3AHumansPharmacologychemistry.chemical_classificationBinding SitesbiologyBile acidCYP3A4Cytochrome P450ArticlesAmino acidEnzyme ActivationchemistryBiochemistrybiology.proteinLithocholic AcidSteroids
researchProduct